Pretreatment absolute lymphocyte count and neutrophil-To-lymphocyte ratio are prognostic factors for stage iii breast cancer

11Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Stage III breast cancer comprises a broad spectrum of disease, including the extent of supraclavicular/internal mammary lymph node metastasis. In this study, we evaluated the usefulness of the absolute lymphocyte count (ALC) and neutrophil-To-lymphocyte ratio (NLR) in predicting the prognosis of patients with stage III breast cancer. Patients and Methods: Seventy-five patients with stage III breast cancer who underwent surgery were included. We compared their clinicopathological factors according to the presence or not of supraclavicular/internal mammary lymph node metastasis, and pretreatment ALC or NLR. Results: Patients with metastasis of the studied lymph nodes had a poorer prognosis in comparison to those without metastasis. In patients without these types of lymph node metastasis, both the ALC and NLR were predictive factors for relapse-free and overall survival. Among these patients, those with a low ALC or high NLR had recurrence-free and overall survival comparable to those of patients with supraclavicular/internal mammary lymph node metastasis. Conclusion: Pretreatment ALC and NLR were prognostic factors for patients with stage III breast cancer.

Author supplied keywords

Cite

CITATION STYLE

APA

Yamanouchi, K., Maeda, S., Takei, D., Koga, Y., Yamashita, M., Hamada, T., … Kuroki, T. (2021). Pretreatment absolute lymphocyte count and neutrophil-To-lymphocyte ratio are prognostic factors for stage iii breast cancer. Anticancer Research, 41(7), 3625–3634. https://doi.org/10.21873/anticanres.15151

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free